An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Inclusion Criteria: * Given written informed consent * Male or female aged ≥ 19 * Primary immune thrombocytopenia (ITP) * Platelet \<20x10\^9 /L * Patients who have taken adrenal cortical hormones and/or other immunosuppressive medications should maintain their stable doses before and during this study Exclusion Criteria: * Patients who have participate in other interventional study within 30 days * Inability in written/verbal communication * Engaged with an elective surgery * Pregnant or breast-feeding women * Women of childbearing potential who do not agree with contraception during this study * Patients who had experienced any hypersensitivity or shock with study drug or active ingredient * Refractory to immunoglobulin therapy * Secondary immune thrombocytopenia * HIV-associated ITP * Lupus-associated ITP * Lymphproliferative disease * Hepatitis virus carrier * Other disease- or infection-associated ITP * Drug-Induced ITP * Hereditary thrombopenia (e.g., MYH9 disorders) * Hemolytic anemia (Positive direct Coomb's test) * Clinically significant abnormalities of immunoglobulin * Immunoglobulin A Deficiency * Immune disorders or deficiency * Alcohol or drug abuse within 6 months * Patients who had taken any medications which may effect platelet function or count for at least 2 days prior study entry * Patients who had administrated with IVIg or anti-D immunoglobulin agents within 1 month * Patients who had undergone a splenectomy within 2 months * Clinically significant underlying disease or medical history at investigator's discretion